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Background: Acute myocardial ischemia results in scar formation with ventricular dilatation 
and eventually heart failure. Placental growth factor (PlGF) is reported to stimulate angiogenesis 
and improve cardiac function. In this study, it was hypothesized that intramyocardial injection 
of PlGF contained in nanoparticles can be released at the site of action for an extended time 
period as a sustained slow-release protective mechanism that accelerates myocardial recovery 
in a rat model of ischemic cardiomyopathy.
Methods: PlGF-loaded chitosan-alginate nanoparticles were injected into an acute myocardial 
infarction model in rats (n = 10 per group). Transthoracic echocardiography was performed at 
different time intervals. Enzyme-linked immunosorbent assay was used to measure the serum 
cytokines levels at 8 weeks. Hearts were stained with Masson’s trichrome for scar area analysis. 
Immunofluorostaining was performed to evaluate the extent of myocardial angiogenesis at the 
infarction border. PlGF enzyme-linked immunosorbent assay was used to measure the in vitro 
release kinetics of PlGF-loaded nanoparticles.
Results: At 8 weeks after coronary ligation, hearts that were treated with PlGF-loaded chitosan-
alginate nanoparticles had significant increases in left-ventricular function (P , 0.01), vascular 
density (P , 0.01), and in the serum level of the anti-inflammatory cytokine interleukin-10 
(P , 0.05). There was significant decrease in scar area formation (P , 0.05) and in serum levels 
of the proinflammatory cytokines tumor necrosis factor-alpha and interleukin-6 (P , 0.01). 
In vitro PlGF-release kinetic studies showed a sustained release of PlGF from the particles 
over a 120-hour period.
Conclusion: The use of nanoparticles as a vehicle for PlGF delivery, as opposed to the direct 
injection of the growth factor after acute myocardial infarction, can provide sustained slow-
release PlGF therapy, enhancing the positive effects of the growth factor in the setting of acute 
myocardial ischemia.
Keywords: nanotechnology, serum cytokines, myocardial therapy, angiogenesis, regenerative 
medicine
Introduction
Myocardial infarction (MI) results in scar formation with ventricular dilatation and 
eventually heart failure. Treatment modalities include medications, heart transplanta-
tion, and implantable left-ventricular assist devices (LVADs). The latter modalities are 
not popular due to the limited supply of organ donors and the high complication rates 
with LVADs.1,2 The ideal therapy should be able to facilitate the production of new 
cardiomyocytes and stimulate revascularization of the ischemic region by promoting 
angiogenesis to preserve cardiac function.3International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Inducing angiogenesis is a novel approach to the treatment 
of myocardial ischemia. Proangiogenic growth factors are 
used to promote the growth and development of new blood 
vessels and, in turn, promote regeneration of the myocardium 
at risk. One of these factors is placental growth factor (PlGF).4 
PlGF is a 50 kDa homodimeric glycoprotein sharing 53% 
sequence homology at the amino acid level with vascular 
endothelial growth factor (VEGF). PlGF is able to bind with 
high affinity to the fms-like tyrosine kinase (Flt-1) receptor 
but not to the kinase domain region receptor, thought to be 
critically involved in mediating VEGF biological action. It is 
able to significantly potentiate the effects of low concentra-
tions of VEGF, both in vitro and in vivo.5 PlGF is reported 
to stimulate angiogenesis with the same efficacy as VEGF 
but without any of the side-effects that normally accompany 
VEGF therapy, such as edema, hypotension, and the forma-
tion of hemangiomas.6
Despite advances in the treatment of MI, a major obstacle 
to drug therapy is the limited access drugs in an active form 
have to the ischemic myocardium. Delivering growth factors 
remains a challenging process as most of these factors do not 
remain at the site of interest (ie, infarcted tissue). Possible 
causes for this include the modes of delivery, local enzymatic 
degradation, differences between animal models, and the 
“washing-out” mechanism of the contracting myocardium.7 
One novel approach to dealing with these problems is to use 
nanoparticles for drug delivery. Nanodelivery systems deal 
with materials and systems whose structures and components 
exhibit novel and significantly improved physical, chemi-
cal, and biological properties due to their nanoscale size.8 
  Multiple types of nanomaterials have been used to deliver 
drugs to certain sites in the body.9,10 Of these, chitosan-
alginate nanoparticles are widely used for their unique 
properties. Firstly, they are biodegradable and biocompatible 
with a very low potential for toxicity. Secondly, they are able 
to induce a prolonged slow release of the material they 
carry. Lastly, these particles provide protection from local 
enzymatic degradation.11,12
In this study, it was hypothesized that intramyocardial 
injection of PlGF contained in chitosan-alginate nanopar-
ticles can provide a sustained slow-release protective mecha-
nism that accelerates myocardial recovery in a rat model of 
ischemic cardiomyopathy.
Materials and methods
Animals
The experiment was performed on female Lewis rats 
(200–250 g; Charles River Laboratories, Senneville, Canada) 
in accordance with the guidelines set forth by the Canadian 
Council on Animal Care and were approved by the institu-
tional ethics committee. Rats were housed in groups of two 
to three per cage, at 23°C, fed with Purina rat ration, and 
were allowed free access to water.
chemicals and growth factor
Low viscosity alginic acid sodium salt from brown algae 
(viscosity: ∼250 centipoise, 2% in water at 25°C) was 
bought from Sigma Chemicals (St Louis, MO). Chitosan 
(low viscosity, Mv = 7.2 × 104 by viscometry, degree of 
deacetylation at 73.5% by titration) was purchased from 
Wako BioProducts (Richmond, VA). Calcium chloride 
was bought from Sigma-Aldrich Canada Ltd (Oakville, 
Canada). Recombinant human PlGF was purchased from 
R&D   Systems Inc   (Minneapolis, MN).
Preparation of chitosan-alginate 
nanospheres
Chitosan-alginate nanospheres were prepared using a method 
modified from Rajaonarivony et al.13 Aqueous calcium chlo-
ride (2 mL of 0.67 mg/mL) was added dropwise to 10 mL 
of aqueous sodium alginate (0.6 mg/mL) while sonicating 
with a microtip probe ultrasonic sonicator (Branson 2510; 
Cleveland, OH) for 1 minute at 50 W. The resultant cal-
cium alginate pre-gel was transferred to a beaker, stirred 
for 30 minutes, and then 2 mL of a 0.3 mg/mL solution of 
chitosan in 3% v/v acetic acid was added and stirred for an 
additional 30 minutes. The resultant suspension was equili-
brated overnight to allow nanospheres to form with uniform 
particle size. These nanospheres were isolated by ultracen-
trifugation at 140,000 g for 60 minutes at 4°C. The resultant 
pellet was redispersed in distilled water by sonicating for 
1 minute, and the nanospheres were washed twice in water 
by ultracentrifugation. The PlGF-loaded nanoparticles were 
formed in the same way by adding CaCl2 solution to alginate 
solution containing 1.0 mg/mL PlGF. The nanoparticles were 
characterized for PlGF encapsulation efficiency (amount of 
PlGF encapsulated with respect to the initial amount of PlGF 
used), as described previously.14
In vitro release kinetics of PlgF-loaded  
chitosan-alginate nanoparticles
For in vitro release kinetics, the PlGF-loaded particles were 
suspended in 20 mL of phosphate-buffered saline (pH 7.4) 
and placed in a thermostatic environment at 37°C with hori-
zontal shaking (100 rpm). At appropriate time intervals, 
1 mL of the medium was periodically removed and replaced International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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with the same quantity of   phosphate-buffered saline. The 
  concentration of PlGF released at different times was 
assayed by PlGF enzyme-linked immunosorbent assay 
(ELISA) (R&D Systems Inc) according to the manu-
facturer’s instructions. All experiments were performed 
in triplicate. The amount of encapsulated protein was 
determined as the difference between the initial amount 
of protein and what remained in the supernatant, measured 
by ELISA.
Morphology and structure  
characterization of nanoparticles
Transmission electron microscopy was used to determine 
the size characterization. Nanoparticles were photographed 
using a CM-200 FEG Transmission Electron Microscope 
(Philips, Markham, Canada). The size was confirmed using 
a particle sizer instrument. The size of the nanoparticles was 
measured by electrophoretic laser Doppler anemometry using 
a Zeta Potential Analyzer (Brookhaven Instruments Corp, 
Holtsville, NY). ZetaPlus Particle Sizer (v 4.11; Brookhaven 
Instruments Corporation) software was used to determine 
the size distribution of the nanoparticles and Zeta Potential 
Analyzer (v 3.57; Brookhaven Instruments Corporation) 
was the software used for the zeta potential. The particle 
sizes were measured for three batches of nanoparticles, and 
each measurement was obtained after taking the average of 
three runs.
Ligation of the left coronary artery and  
intramyocardial injection of nanoparticles
The surgery was performed as previously described.7 Briefly, 
rats were anesthetized using 5% isoflurane, intubated, and 
mechanically ventilated at 80 breaths/minute. Via a left 
thoracotomy (through the fourth intercostal space), the 
left anterior descending coronary artery was permanently 
ligated 2 mm from its origin with a 7/0 polypropylene suture 
(Ethicon Inc, Somerville, NJ). The ischemic myocardial 
segment rapidly became identifiable through its pallor and 
akinesia corresponding to the distribution of the left anterior 
descending coronary artery territory distal to the occlusion, 
which resulted in MI of the free left ventricle (LV) and sub-
sequently heart failure. Fifteen minutes after ligation of the 
artery, three equal peri-infarct intramyocardial injections 
were performed using a 27-G needle. Rats were random-
ized into four groups: control group I (n = 10) received 
empty chitosan-alginate nanoparticles, treatment group II 
(n = 10) received intramyocardial injection of 1 µg of PlGF 
in 300 µL of saline into the border zone, and treatment group 
III (n = 10) received intramyocardial injection of 1 µg of PlGF 
contained in chitosan-alginate nanoparticles in 300 µL of 
saline (Figure 1). All of these groups had coronary ligation 
and injection of material into the peri-infarcted area. The final 
group, group IV , was a sham-operated group (n = 5). Sham 
and control animals were similarly handled, except that the 
suture around the coronary artery was not tied. The reason 
Chitosan-alginate nanoparticles PIGF PIGF-loaded nanoparticles
In vivo studies of the infarcted heart
-     Ejection fraction
-     Scar area
-     Capillary and arteriole density
-     Serum TNF-α and IL-6
-     Serum IL-10
+
Figure 1 schematic representation of placental growth factor (PlgF) encapsulation with chitosan-alginate nanoparticles and subsequent intramyocardial delivery to the 
infarcted rat heart. Its therapeutic effects include increase in cardiac function, decrease in scar area formation, increase in angiogenesis, decrease in proinflammatory serum 
cytokines levels, and an increase in the anti-inflammatory serum cytokine level of IL-10.
Abbreviations: IL, interleukin; TNF-α, tumor necrosis factor-alpha.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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for using empty nanoparticles as a control was to ensure that 
these particles had no positive impact on cardiac function 
and the choice of dosage of PlGF was based on a previous 
study that showed its efficacy in cardiac function improve-
ment in rats.4 Body weight, general behavior, and mortality 
of the animals were monitored on a regular basis.
echocardiography
Echocardiographic examinations were performed under 
inhaled isoflurane anesthesia (2.5% in oxygen, 500–700 mL/
minute). Transthoracic echocardiography was performed for 
each rat as a baseline before the surgery, after ligation at 
2 days, 1 week, and 4 weeks, and at 8 weeks. Echocardio-
grams were obtained with a commercially available system 
(Micromaxx P04224; SonoSite, Bothell, WA), equipped with 
a linear probe 7–13 MHz 25 mm footprint turbo transducer 
(P06519.11; SonoSite). Briefly, LV end-diastolic diameters 
(LVEDD) and end-systolic diameters (LVESD) were mea-
sured with M-mode tracings between the anterior and poste-
rior walls from the parasternal short-axis view just below the 
level of the papillary muscles of the mitral valve. The time 
of end-diastole was defined as time of maximum diameter 
of the LV in one heart cycle. Accordingly, end-systole was 
defined as the minimum diameter. Following the American 
Society of Echocardiology leading-edge method, two images 
on average were obtained in each view and averaged over 
three consecutive cycles.15 Left-ventricular fractional short-
ening (LVFS) was determined as = [(LVEDD - LVESD)/
LVEDD] × 100. The left-ventricular end-diastolic volume 
(LVEDV) and left-ventricular end-systolic volume (LVESV) 
were measured using the Teichholz formula: LVEDV was 
calculated as 7.0 × LVEDD3/(2.4 + LVEDD), and LVESV as 
7.0 × LVESD3/(2.4 + LVESD).16 The left ventricular ejection 
fraction (LVEF) was determined as
 
LVEF
LV end-diastolic volumeL V end-systolic volume
LV end-
=
-
d diastolic volume
scar area analysis
Eight weeks postoperation, rats were deeply anesthetized 
and sacrificed by rapid excision of the heart. Scar area 
analysis was performed as previously described.17 Briefly, 
the excised hearts were immediately soaked in cold saline 
to remove excess blood from the ventricles and then fixed in 
neutral-buffered 4% formalin. Paraffin-embedded samples 
were sectioned at 5 µm, and Masson’s trichrome staining 
(DBS, Pleasanton, CA) was performed to delineate scar tissue 
(blue color) from the total area of myocardium. Masson’s 
trichrome-stained sections were captured as digital images 
and analyzed by ImageJ (v 1.41; National Institutes of Health, 
Bethesda, MD) software. Infarct areas were calculated and 
expressed as a percentage.
Angiogenesis assessment
Neovascularization was evaluated by analyzing the capil-
lary and arteriole density in the peri-infarct area. For this, 
immunofluorostaining was performed with antibodies 
against platelet endothelial cell adhesion molecule (Santa 
Cruz Biotechnology Inc, Santa Cruz, CA) for identification 
of endothelial cells and smooth muscle α-actin (Santa Cruz 
Biotechnology Inc) for tracing the smooth muscle cells.18,19 
Briefly, for measurement of capillary density, five fields in 
the peri-infarct area were imaged and average numbers of 
capillaries with diameter ,10 µm were counted. The capil-
lary density was quantified as the (mean total CD31-positive 
microvessels)/mm2 using three tissue sections spanning 
the peri-infarct tissue region of each animal. Similarly, 
arteriole densities were quantified as (mean total smooth 
muscle α-actin-positive microvessels)/mm2.
serum concentration of soluble cytokines
At 8 weeks and before harvesting the hearts, blood samples 
were collected from the left atrium of each rat by direct car-
diac puncture. Samples were then centrifuged at 14000 rpm 
for 10 minutes. After that, samples were stored at -20°C until 
analysis. As described previously,20 serum levels of interleu-
kin (IL)-10, tumor necrosis factor-alpha (TNF-α), and IL-6 
were measured using commercially available Rat Inflam-
matory Cytokines Multi-Analyte ELISArray Kit (SABiosci-
ences, QIAGEN Company, Frederick, MD). The kit format 
was microtiter plates precoated with a murine monoclonal 
antibody against the rat cytokine being measured. Standards 
of the analyte and serum samples were added in duplicate. 
Fifty microliters of the sample was added to the appropriate 
wells of the ELISA strips. The samples were incubated for 
2 hours. Then 100 µL of detection antibody solution was 
pipetted and incubated for 1 hour at room temperature. One 
hundred microliters of avidin-horseradish peroxidase (HRP) 
solution was added to all wells and incubated for 30 minutes 
at room temperature. After that, 100 µL of development 
solution (tetramethylbenzidine) was added to each well and 
incubated for 15 minutes at room temperature in the dark. 
Finally, 100 µL of stop solution (1 M sulfuric acid) was 
added to each well. The color changes from blue to yellow 
and the absorbance were read at 450 nm within 30 minutes 
of stopping the reaction and standard curves were plotted. International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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All assays were conducted in a blinded fashion. The intra- and 
interassay coefficients of variation in the laboratory were 
below 10%.
statistical analysis
All statistical analyses were carried out using the GraphPad 
Prism (v 5.00; GraphPad Software, La Jolla, CA) software. 
All statistical tests were two-tailed. P values of #0.05 were 
considered indicative of statistical significance. All data are 
expressed as mean ± standard deviation (SD).
repeated measurements of LVFs and LVeF
Repeated echocardiographic variables at baseline, 2 days, 
1 week, and 4 weeks, and 8 weeks postinfarct were compared 
by means of two-way repeated-measures analysis of variance 
(ANOVA). Preliminary checks were conducted to ensure 
that there was no violation of the assumptions of normality, 
  linearity, homogeneity of variances, and homogeneity of regres-
sion slopes. If a significant F ratio was obtained, a   Bonferroni 
post hoc test was used to assess pairwise differences.
scar area percentage, capillary density, arteriolar  
density, and cytokines concentration
One-way ANOVA was used to compare mean percentage scar 
area, capillary density, arteriolar density, and serum cytokine 
level among the groups. Post hoc comparisons of means were 
performed with the Bonferroni method for the adjustment 
of P values and 95% confidence intervals (CIs) for multiple 
testing, which is recommended for balanced ANOVA.
Results
sample size and mortality
Forty-three female Lewis rats were included in the study. 
A mortality rate of 23% (eight rats) was observed, with a 
total of 35 rats surviving to the experimental endpoint at 
2 months. All of the mortalities occurred during the first 
48 hours after coronary ligation. There was no significant 
difference in mortality among the different groups. No late 
deaths were observed in the surviving rats.
characterization of nanoparticles
Electron microscopy analysis confirmed the presence of 
nanoparticles and provided morphological information on 
the typical PlGF-loaded chitosan-alginate nanoparticles. 
Using transmission electron microscopy, the particles were 
about 100–200 nm in diameter (Figure 2A), and spherical 
in shape. However, the nanoparticles did not appear to have 
smooth surfaces but rather “fluffy” surfaces. These particles 
had a positive Zeta potential 7.2 ± 0.5 mV . The encapsulation 
efficiency was found to be 38.4% ± 3.4%.
In vitro release kinetics
The concentration of PlGF released at different times was 
assayed and showed a biphasic release model in the in vitro 
release study. During the first 24 hours, there was limited drug 
release but at 48 hours there was a rapid release of the growth 
factor due to the gradual degradation of the nanoparticles 
over time. There was no drug release after 120 hours. The 
release of PlGF from chitosan-alginate nanoparticles over 
time is illustrated in Figure 2B. This release pattern can be 
controlled depending on the concentration of alginate used 
in the preparation of the nanoparticles.
echocardiography measurements
LVFs measurements
The LV fractional shortening was not significantly different 
among the groups preoperatively or even 2 days postinfarct 
(P . 0.05). Two-way ANOVA showed that there was 
a significant difference between the groups in the mean 
LVFS at 1 week postinfarct. Post-hoc comparisons showed 
that mean LVFS at 1 week postinfarct for group II was not 
statistically significant compared with group III (95% CI 
[-4.3, 3.9], P . 0.05). However, mean LVFS values at 
1 week postinfarct for group II and group III were higher than 
the mean LVFS for group I and the differences were statisti-
cally significant, with differences of 5.3% (95% CI [1.2, 9.4], 
P , 0.001) and 5.1% (95% CI [1.01, 9.2], P , 0.01), 
respectively. Moreover, two-way ANOVA showed that 
there was a significant difference between the groups in the 
mean LVFS at 4 weeks postinfarct. Post-hoc comparisons 
showed that mean LVFS at 4 weeks postinfarct for group II 
was statistically significant compared with group III (95% 
CI [-0.3, 7.9], P , 0.05). The mean LVFS values at 4 weeks 
postinfarct for group II and group III were higher than the 
mean LVFS for group I and the differences were statistically 
significant, with differences of 9.6% (95% CI [5.3, 13.5], 
P , 0.001) and 13.2% (95% CI [9.1, 17.3], P , 0.001), 
respectively.   Similarly, two-way ANOVA showed that 
there was a significant difference between the groups in the 
mean LVFS at 8 weeks postinfarct. Post-hoc comparisons 
showed that mean LVFS at 8 weeks postinfarct for group II 
was statistically significant compared with group III (95% 
CI [-0.2, 8], P , 0.05). The means at 8 weeks postinfarct 
for group II and group III were higher than the mean LVFS 
for group I and the differences were statistically significant, 
with differences of 10.4% (95% CI [6.3, 14.5], P , 0.001) International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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and 14.3% (95% CI [10.2, 18.4], P , 0.001), respectively. 
The means and SDs of LVFS at baseline, 2 days, 1 week, 4 
weeks, and 8 weeks postinfarct are shown in Figure 3E.
LVeF measurements
The LV ejection fraction was not significantly different 
among the groups preoperatively or even at 2 days postin-
farct (P . 0.05). Two-way ANOVA showed that there was 
a significant difference between the groups in the mean 
LVEF at 1 week postinfarct. Post-hoc comparisons showed 
that the mean LVEF at 1 week postinfarct for group II was 
not statistically significant compared with group III (95% 
CI [-6.9, 5.5], P . 0.05). However, mean LVEF values at 
1 week postinfarct for group II and group III were higher than 
the mean LVEF for group I and the differences were statisti-
cally significant, with differences of 7.2% (95% CI [1.01, 
13.4], P , 0.01) and 6.4% (95% CI [0.3, 12.7], P , 0.05), 
respectively. Moreover, two-way ANOVA showed that 
there was a significant difference between the groups in the 
mean LVEF at 4 weeks postinfarct. Post-hoc comparisons 
showed that mean LVEF at 4 weeks postinfarct for group II 
was statistically significant compared with group III (95% CI 
(-4.3, 16.7), P , 0.001). The mean LVEF values at 4 weeks 
postinfarct for group II and group III were higher than the 
mean LVEF for group I and the differences were statistically 
significant, with differences of 17% (95% CI (10.8, 23.2), 
P , 0.001), and 27.5% (95% CI (21.3, 33.7), P , 0.001) 
respectively. Similarly, two-way ANOVA showed that there 
was a significant difference between the groups in the mean 
LVEF at 8 weeks postinfarct. Post-hoc comparisons showed 
that the mean LVEF at 8 weeks postinfarct for group II was 
statistically significant compared with group III (95% CI 
[3.3, 15.7], P , 0.001). The means at 8 weeks postinfarct 
for group II and group III were higher than the mean LVEF 
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for group I and the differences were statistically significant, 
with differences of 19.5% (95% CI [13.3, 25.7], P , 0.001) 
and 29% (95% CI [22.8, 35.2], P , 0.001) respectively. The 
means and SDs of LVEF at baseline, 2 days, 1 week, 4 weeks, 
and 8 weeks postinfarct are shown in Figure 3F.
scar area measurements
One-way ANOVA showed that there was a significant 
difference among the groups in the mean scar area per-
centage at 8 weeks postinfarct. Scar area percentage was 
significantly different between the groups (32.7% ± 4% in 
group I versus 28.4% ± 3% in group II, 95% CI [0.61, 8] 
P , 0.01; 28.4% ± 3% in group II versus 24.5% ± 2.6% 
in group III, 95% CI [0.2, 7.6] P , 0.01; 32.7% ± 4% in 
group I versus 24.5% ± 2.6% in group III, 95% CI [4.5, 
11.9] P , 0.0001). Mean percent scar and SD per group are 
presented in Figure 4.
Angiogenesis measurements
One-way ANOVA showed that there was a significant 
  difference between the groups in the mean capillary den-
sity at 8 weeks postinfarct. Capillary density, quantified 
as (mean total CD31-positive microvessels)/mm2, was 
significantly different between the groups (33.3 ± 11.7 
total CD31-  positive microvessels/mm2 in group I versus 
80.8 ± 20.4 total CD31-positive microvessels/mm2 in group 
II, 95% CI [-66.2, -28.8] P , 0.0001; 80.8 ± 20.4 total CD31-
positive microvessels/mm2 in group II versus 128.7 ± 15.9 
total CD31-positive microvessels/mm2 in group III, 95% 
CI [-66.6, -29.2] P , 0.0001; 33.3 ± 11.7 total CD31-
positive microvessels/mm2 in group I versus 128.7 ± 15.9 
total CD31-positive microvessels/mm2 in group III, 95% CI 
[-114.1, -76.7] P , 0.0001) (Figure 5A–C). Mean capillary 
density and SD per group are presented in Figure 5G.
One-way ANOVA showed that there was a signifi-
cant difference between the groups in the mean arteriole 
density at 8 weeks postinfarct. Arteriolar density, quan-
tified as (mean total smooth muscle α-actin-positive 
microvessels)/mm2, was significantly different between 
the groups (4.3 ± 1.9 total smooth muscle α-actin-positive 
microvessels/mm2 in group I versus 9.8 ± 3.6 total smooth 
muscle α-actin-positive microvessels/mm2 in group II, 
95% CI [-8.6, -2.3] P , 0.0001; 9.8 ± 3.6 total smooth 
muscle α-actin-positive microvessels/mm2 in group II 
versus 13.3 ± 2.5 total smooth muscle α-actin-positive 
microvessels/mm2 in group III, 95% CI [-6.76, -0.3] 
P , 0.01; 4.3 ± 1.9 total smooth muscle α-actin-positive 
  microvessels/mm2 in group I versus 13.3 ± 2.5 total smooth 
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muscle α-actin-positive   microvessels/mm2 in group III, 95% 
CI [-12.12, -5.8] P , 0.0001)   (Figure 5D–F). Mean arteri-
ole density and SD per group are presented in Figure 5H.
serum cytokines measurements
One-way ANOVA showed that there was a significant 
  difference between the groups in the mean cytokine levels at 
8 weeks postinfarct. Serum TNF-α levels were significantly 
different between the groups (Figure 6A, 16.6 ± 4.1 pg/mL 
in group I versus 11.1 ± 3 pg/mL in group II, 95% CI 
[1.2, 7.8] P , 0.01; 11.1 ± 3 pg/mL in group II versus 
7.1 ± 2.2 pg/mL in group III, 95% CI [0.7, 7.3] P , 0.022; 
16.6 ± 4.1 pg/mL in group I versus 7.1 ± 2.2 pg/mL in 
group III, 95% CI [5.2, 11.8] P , 0.0001). Serum IL-6 levels 
were significantly different between the groups (Figure 6B, 
145.5 ± 28.5 pg/mL in group I versus 105.7 ± 16.8 pg/mL in 
group II, 95% CI [10.3, 59.3] P , 0.01; 105.7 ± 16.8 pg/mL 
in group II versus 75.4 ± 19.2 pg/mL in group III, 95% CI 
[5.8, 54.8] P , 0.01; 145.5 ± 28.5 pg/mL in group I ver-
sus 75.4 ± 19.2 pg/mL in group III, 95% CI [40.6, 89.6] 
P , 0.0001). However, the anti-inflammatory cytokine IL-10 
was significantly increased in group III compared with the 
other groups at 8 weeks postinfarct (Figure 6C, 0.9 ± 0.5 pg/mL 
in group I versus 1.5 ± 0.5 pg/mL in group II, 95% CI [-1.4, 
-0.04] P , 0.01; 1.5 ± 0.5 pg/mL in group II versus 
2.3 ± 0.6 pg/mL in group III, 95% CI [-1.5, -0.1] P , 0.01; 
0.9 ± 0.5 pg/mL in group I versus 2.3 ± 0.6 pg/mL in 
group III, 95% CI [-2.2, -0.8] P , 0.0001).
Discussion
Heart failure occurs most commonly as a consequence of 
ischemic heart disease.21 One novel approach for treating 
ischemic heart disease is angiogenesis. PlGF has been used 
for this purpose for almost two decades. PlGF is a 50 kDa 
homodimeric glycoprotein sharing 53% sequence homol-
ogy at the amino acid level with VEGF. Three isoforms 
resulting from alternative splicing are described: PlGF-1 
and PlGF-2, which are identical except for the insertion of 
a heparin-binding domain at the carboxyl end of PlGF-2, 
and the longest isoform, PlGF-3. In this study, PlGF-2 was 
the isomer used.22 PlGF is a unique proangiogenic growth 
factor compared with others because of its action on three 
cell types – endothelial cells, inflammatory cells, and smooth 
muscle cells – to promote neovascularization.23 It induces 
angiogenesis by binding to Flt-1 (VEGF-R1), which leads to 
the activation of fetal liver kinase 1 (VEGF-R2) and, there-
fore, potentiates the effects of VEGF and provides a positive 
feedback.24 Furthermore, PlGF stimulates the mobilization 
of VEGFR1+ hematopoietic cells from the bone mar-
row into circulation, which contributes to postischemic 
  revascularization.25 Several studies have been conducted dem-
onstrating the effect of PlGF on cardiomyocytes. It has been 
shown that the administration of PlGF after an acute MI in 
mice, via an osmotic minipump (continuous infusion), resulted 
in a significant increase in left ventricular ejection fraction, 
significant reduction in the scar area, significant increase in 
left ventricular wall thickness, significant decrease in left 
ventricular dilatation, and remodeling suppression.26 During 
hypoxic conditions, as in MI, cardiomyocytes’ PlGF expres-
sion is upregulated significantly by hypoxia in vitro as well 
as in vivo after myocardial damage. These results provide 
important evidence that endogenous PlGF may facilitate 
cardiac healing after myocardial hypoxic ischemic damage.27 
Kolakowski and colleagues were able to demonstrate the 
beneficial effects of PlGF on the infarcted heart after direct 
myocardial injection.4 In the present study, similar results 
were obtained when comparing groups I and II in regards to 
LVEF, scar area, and angiogenesis analysis. Protein delivery 
was optimized by using the same PlGF dosage as in previous 
studies but with better results due to the use of nanoparticles 
as the drug delivery system.4
Nanoparticles are submicron particles containing 
entrapped drugs. The nanoparticles allow these drugs to be 
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released over a certain period of time in an unaltered state.28 
It has been shown that long-lasting responses (6 months) 
can be obtained using low molecular weight chitosan 
nanoparticles and also that the response is not influenced 
by the drug dose, thus achieving a significant response at 
a very low dose.29 Kundu et al found that in vitro VEGF 
release from silk fibroin nanoparticles showed a signifi-
cantly sustained release over 3 weeks, providing evidence 
of the potential application of nanoparticles as a growth 
factor delivery system.30 In this study, the release kinetics of 
PlGF-loaded chitosan-alginate nanoparticles were assessed 
both in vitro and in vivo. To the authors’ knowledge, this is 
the first report of direct intramyocardial injection of PlGF 
contained in nanoparticles as a revascularization strategy 
for acute MI.
The recovery of heart function was evaluated by measur-
ing both LVFS and LVEF. LVFS for group I reached 16.5% 
at 8 weeks post-MI. This result is comparable to the authors’ 
previous study that examined LVFS for a control group that 
received only culture medium at 7 weeks.7 This comparison 
proves that the nanoparticles used had no negative effect on 
the heart. For group II, LVFS decreased initially as a response 
to the MI but started to increase after 2 days till it plateaued at 
1 week. However, the LVFS for group III started to increase 
2 days postinfarct and plateaued at 4 weeks. The same effect 
happened with LVEF. The possible reason for such a large 
discrepancy between the in vitro release time of PlGF from 
the nanoparticles and the improved cardiac performance 
at 4 weeks is the recovery time of the myocardium. After 
acute MI, the myocardium goes into a hibernating state or 
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what is called “myocardial stunning.” This abnormality can 
persist for weeks or months and is potentially reversible by 
revascularization. After revascularization, the recovery of the 
viable myocardium takes time and is not immediate even after 
complete revascularization.31,32 In this study, revascularization 
was accomplished by PlGF injection. The in vitro release 
of PlGF from the nanoparticles reached a plateau on day 5, 
while in group II, which received PlGF alone, the growth 
factor was all released immediately after injection. PlGF in 
group II was unprotected from the local environment and 
hence most of it was lost. In group III, PlGF was protected 
by the nanoparticles with sustained release for 5 days. This 
resulted in much more angiogenesis in group III compared 
with group II. The myocardium would take time to recover as 
most of it is in the hibernating state. As expected, the results 
of this study indicate that delivering PlGF in nanoparticles 
increases cardiac function compared to injection of either 
empty nanoparticles or PlGF alone. Furthermore, it suggests 
that the chitosan-alginate nanoparticles provide a protective 
sustained-release mechanism for PlGF for a period of time 
postinfarct, which is comparable to the authors’ in vitro 
release kinetic studies of the particles. It can be assumed that 
these particles protected PlGF from local enzymatic degrada-
tion, thus prolonging the action of the growth factor.
To investigate this further and to clarify the mechanism 
underlying the beneficial effects of PlGF in acute MI, scar 
area, angiogenesis, and arteriogenesis were analyzed. Angio-
genesis is considered a potential mechanism in the treatment 
of ischemia by improving blood flow and increasing oxygen 
availability at the MI border zone.33 As expected, scar area 
percentage for group III decreased significantly and this 
correlates with the improvement in LVEF. Furthermore, 
antibodies against platelet endothelial cell adhesion molecule 
and anti-smooth muscle antibody staining demonstrated 
significantly higher capillary and arteriolar densities at the 
border zone of the infarct in group III compared with the other 
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groups, which indicates a higher angiogenesis potential for 
PlGF contained in nanoparticles, despite using the same dose 
of PlGF. It has been previously shown that systemic PlGF 
administration causes remote hypertrophy of the noninfarcted 
myocardium by modifying the capillary/cardiomyocyte ratio. 
This hypertrophy contributed significantly to the recovery 
of the myocardium and had no negative effects.34 This was 
not assessed in the present study as focus was on the peri-
infarcted region.
The significant changes in LVEF, scar area, and arte-
riolar density were accompanied by a significant change in 
serum cytokine levels. Previous studies focused on the tissue 
expression of cytokines post-MI, while a small number of 
studies actually focused on the changes in serum levels of 
these cytokines.35,36 For this reason, it was decided to study 
the serum levels instead of the gene expression. Focus was 
mainly on serum levels of TNF-α, IL-6, and IL-10. TNF-α 
and IL-6 have a negative impact on the infarcted myocar-
dium by causing remodeling, while IL-10 counteracts this 
effect.35 Serum levels of the proinflammatory cytokines 
TNF-α and IL-6 were significantly lower in group III com-
pared with the other groups. Furthermore, the serum level 
of the anti-inflammatory cardioprotective cytokine IL-10 
was significantly higher in group III. This group had less 
left-ventricular remodeling than the other groups based on 
the minimal change in LVEDD and LVESD from baseline as 
shown in Figure 3A–D (detailed data is not shown), as well 
as the decrease in scar formation. It is not unusual to see per-
sistently high levels of pro-inflammatory cytokines 8 weeks 
after MI, as the remodeling process may continue for weeks 
or months post-MI.36 Furthermore, it has been shown that 
plasma TNF-α was significantly elevated in rats by 2 weeks 
after MI and gradually increased to a peak value at week 8.37 
Similarly, the beneficial effect of mesenchymal stem-cell 
therapy on myocardial remodeling through a decrease in the 
proinflammatory/anti-inflammatory cytokine ratio has been 
demonstrated previously by the authors’ group.17
Direct intramyocardial injection of drugs, as opposed to 
other delivery approaches (ie, intravenous or oral), offers 
the delivery of a relatively high concentration of drugs and 
the precise targeting of the peri-infarcted tissue. However, 
one of its drawbacks is its invasiveness. It would be suitable 
only for patients who are undergoing open heart surgery or 
catheter-based interventions. To overcome this problem, a 
better approach needs to be designed. This can be done by 
modifying the surface characteristics of the nanoparticles 
to make them site specific. To combine stem-cell therapy 
and multiple factors with different molecular mechanisms 
to promote cell growth that protect the ischemic (infarcted) 
area from future damage will be an exciting future research 
endeavor. For example, the use of a specific mixture of growth 
factors (such as angiopioten, bFGF, and VEGF) contained in 
a protective sustained-release mechanism (such as micropar-
ticles or nanoparticles), which allows site-specific targeted 
delivery (for example, using receptor-specific antibodies like 
antimyosin light chain antibody), will further define the future 
of cell-based therapy for myocardial regeneration. This will 
allow cell-based therapy to be delivered intravenously rather 
than intramyocardially to the infarcted area and prevent it 
from being washed out by the contracting muscle.
Conclusion
The use of nanoparticles as a vehicle for PlGF delivery as 
opposed to the direct application of the growth factor after 
acute MI resulted in significant increase in LV function, vas-
cular density, and the anti-inflammatory cytokine IL-10, with 
significant decrease in scar area formation and in proinflam-
matory cytokines TNF-α and IL-6. Thus, nanoparticles can 
be used to provide a sustained slow-release protective PlGF 
therapy, enhancing the positive effects of the growth factor 
in the setting of acute myocardial ischemia. Furthermore, 
this nanotechnology can be used as a drug delivery system 
for many anti-heart failure medications. This would retain 
most of the drug at the site of interest as well as minimiz-
ing systemic toxicity. Further experiments and studies are 
needed to optimize the method, which may lead to a new era 
in therapeutics.
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